Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy
Clinical Journal of the American Society of Nephrology · 2026
DOI: 10.2215/cjn.0000000932 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Journal of the American Society of Nephrology, 2026. Verfasst von Jair Munoz Mendoza und 11 weiteren Autor:innen. Beteiligte Einrichtung: Katz Family Division of Nephrology and Hypertension, Department of Medicine, Peggy and Harold Katz Family Drug Discovery Center, University of Miami,…. Hauptthemen laut MEDLINE: Nephrectomy, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Albuminuria. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Bayer AG.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Key Points Finerenone reduced albuminuria versus placebo in patients with a history of nephrectomy, similar to those without a history of nephrectomy. Incidences of treatment-emergent adverse events or serious adverse events were generally similar in patients with and without history of nephrectomy. Finerenone may delay kidney disease progression in patients with CKD and type 2 diabetes, irrespective of nephrectomy status.
Background
Finerenone significantly reduced the risk of cardiovascular and kidney outcomes in patients with CKD and type 2 diabetes (T2D) in FIDELITY, a prespecified pooled analysis of two phase 3 trials. This post hoc FIDELITY analysis examined the efficacy and safety of finerenone in patients with CKD, T2D, and a history of nephrectomy.
Methods
Patients in FIDELITY were randomized to receive finerenone or placebo and were on optimized renin–angiotensin system inhibition. We identified nephrectomy status using patients' medical history and assessed CKD progression in patients by nephrectomy status at baseline by modeling change in urine albumin-to-creatinine ratio from baseline to months 4–24. Safety outcomes included treatment-emergent adverse events and incident hyperkalemia.
Results
Of 12,990 patients, 108 had a history of nephrectomy at baseline; 101 of 108 had radical nephrectomy, 55 received finerenone, and 53 received placebo. Baseline mean eGFR were numerically lower in patients with a history of nephrectomy (48±17 ml/min per 1.73 m 2 ) than in patients without (58±22 ml/min per 1.73 m 2 ). For patients with a history of nephrectomy, those who received finerenone had a greater urine albumin-to-creatinine ratio reduction at 4 months versus those who received placebo (least-squares mean ratio to baseline, 0.65 versus 1.09; least-squares mean treatment ratio, 0.60; 95% confidence interval, 0.48 to 0.76; P < 0.001). This reduction was maintained for 2 years. Treatment-emergent adverse events were similar in patients with and without a history of nephrectomy. Among patients with a history of nephrectomy, treatment-emergent hyperkalemia occurred in 7% and 6% of finerenone and placebo groups, respectively.
Conclusions
Finerenone reduced albuminuria compared with placebo and demonstrated a safety profile consistent with the overall FIDELITY population in patients with and without a history of nephrectomy at baseline. Finerenone may delay CKD progression and associated morbidity in patients with CKD and T2D, irrespective of nephrectomy status. Clinical Trial registry name and registration number: FIDELIO-DKD (NCT02540993); FIGARO-DKD (NCT02545049).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Katz Family Division of Nephrology and Hypertension, Department of Medicine, Peggy and Harold Katz Family Drug Discovery Center, University of Miami, Miller School of Medicine, Miami, Florida.
- Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland.
- Department of Cardiology (CVK) of German Heart Center Charité, German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.
- Department of Cardiology, School of Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Jair Munoz Mendoza, Matthew R Weir, Gerasimos Filippatos, Peter Rossing, Meike Brinker, Alessia Fornoni
Förderung
- Bayer AG
Zitieren
APA
Munoz Mendoza, J., Weir, M. R., Anker, S. D., Filippatos, G., Rossing, P., Ahlers, C., Brinker, M., Fatoba, S. T., Horvat-Broecker, A., Rohwedder, K., Fornoni, A., & FIDELIO-DKD and FIGARO-DKD Investigators (2026). Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000000932
Vancouver
Munoz Mendoza J, Weir MR, Anker SD, Filippatos G, Rossing P, Ahlers C, et al. Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000000932
BibTeX
@article{MunozMendoza2026,
author = {Munoz Mendoza, Jair and Weir, Matthew R and Anker, Stefan D and Filippatos, Gerasimos and Rossing, Peter and Ahlers, Christiane and Brinker, Meike and Fatoba, Samuel T and Horvat-Broecker, Andrea and Rohwedder, Katja and Fornoni, Alessia and FIDELIO-DKD and FIGARO-DKD Investigators, FIDELIO-DKD and FIGARO-DKD Investigators},
title = {Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000000932}
}
EUVIMED